Companies · Biotech
San Francisco · CA, USA; Berkeley, CA, USA · Biotech · founded 2021 · http://www.bluumbio.com
Diligence memoA one-page analyst read on BLUUMBIO — recommendation, valuation, rhythm, risks.→BLUUMBIO: limited disclosed financing to assess.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
BLUUMBIO is one of 233 Biotech companies tracked from San Francisco, CA, USA; Berkeley, CA, USA, on record since 2021. By capital raised it ranks mid-pack (ahead of 67% of sector peers), and mid-pack by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
We make bacteria and plants that clean up pollution.
Our mission -To ensure current and future generations have access to clean soil, water & air. -To protect and restore earth's beautiful and diverse ecosystems. -To undo the harm of industrial activity on the planet and ensure future industrial activities are more sustainable. Our research -We develop new bio-based solutions that break down and remove toxic chemicals from the environment. We also develop bioreactor based solutions which remove toxins from industrial production pipelines, ensuring contaminants are never released into the environment. -To do this, we've partnered with Nature. Specifically, we have harnessed the power of one of Nature's smallest but most powerful technologies: enzymes. Enzymes are everywhere. They break down the food in your stomach, remove dirt from your clothes, and make our beer. At BluumBio, we look for enzymes found in bacteria, algae, plants and other living organisms that naturally degrade toxic chemicals. We then make these enzymes work better in the lab and come up with develop new applications for these technologies.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
No round amounts on record to chart.
No staged rounds to sequence.
Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 233 companies in Biotech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 67% of sector peers (real $). Modeled value above 67% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| No rounds recorded. | |||||
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
BLUUMBIO is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| 10x Science | Biotech | — | — | — | same sector |
| 1849 bio | Biotech | — | — | — | same sector |
| 1910 | Biotech | — | — | — | same sector |
| 20n | Biotech | — | — | — | same sector |
| 54Gene, Inc. | Biotech | Series B | $48.3M | $598.4M | same sector |
| Abacus Bioscience Inc. | Biotech | Series A | $4.4M | $46.6M | same sector |
| Abalone Bio | Biotech | — | — | — | same sector |
| Acoustic Wave Cell Therapy, Inc. | Biotech | Series A | $20.5M | $84.9M | same sector |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Birch Biosciences We recycle plastic using engineered enzymes | Biotech | — | — | 78% |
| Cascade Biocatalysts, Inc. | Biotechnology | Series A | $16.8M | 76% |
| Solugen, Inc. Decarbonizing the chemicals industry. | Climate / Cleantech | Series D+ | $6.9B | 76% |
| Lygos, Inc. Lygos engineers yeast to convert sugar into high-value industrial… | Biotech | Series B | $432.7M | 75% |
| Alga Biosciences We stop cows from burping methane. | Biotech | — | — | 75% |
| Living Carbon maximizing biomass on low quality land | Biotech | — | — | 75% |
| Bariendo Inc. | Biotechnology | Series A | $40.9M | 74% |
| Clear Creek Bio, Inc. | Biotechnology | Series A | $37.1M | 74% |
See where BLUUMBIO sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at BLUUMBIO, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.